Table 1.
A comparison of the clinical characteristics between CS and non-CS patients.
| Variables | Conversion Surgery | p-Value | |
|---|---|---|---|
| (+) (n = 20) | (−) (n = 378) | ||
| age (years), median (range) | 65 (44–83) | 69 (33–87) | 0.25 |
| gender (M/F), n | (10/10) | (207/171) | 0.656 |
| tumor location (Ph/Pb,Pt), n | (14/6) | (218/160) | 0.282 |
| unresectability status (UR-LA vs UR-M), n | (9/11) | (243/135) | 0.622 |
| CEA, median (range) (U/mL) | 3.4 (1.1–9.4) | 4.0(0.3–845) | 0.51 |
| CA19-9, median (range) (U/mL) | 2577 (0.6–1985) | 211(0.6–50,000) | 0.17 |
| tumor size, median (range) (mm) | 30 (18–50) | 35(8–116) | 0.323 |
| T(4/3), n | (16/4) | (332/46) | 0.385 |
| N(1/0), n | (7/13) | (136/252) | 0.917 |
| M(1/0), n | (11/9) | (197/181) | 0.829 |
M, male; F, female; CS, conversion surgery; Ph, pancreatic head; Pb, pancreatic body; Pt, pancreatic tail; UR-LA, unresectable locally advanced cancer; UR-M, unresectable cancer with metastasis. T, N, and M were classified according to the Tumor-Node-Metastasis (TNM) classification.